AZ ROC: CR-42 320942
title icon

2012 AACR Poster: Phase I Clinical Study of Synergistic Antitumor Activity of MK2206 and TUSC2/FUS1-nanoparticle in NSCLC

TUSC2, a novel tumor suppressor gene in the human chromosome 3p21.3 region, is deleted in many cancers. A phase I clinical trial assessing TUSC2-mediated molecular therapy has reported antitumor activity in lung cancer patients. Previous studies showed that TUSC2 regulates the activation of multiple oncogenic kinases. MK2206 is a highly selective non-ATP-competitive allosteric inhibitor of AKT currently being evaluated in early-phase clinical trials for treatment of patients with lung cancer.